2020
Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol
Ghonem NS, Auclair AM, Hemme CL, Gallucci GM, de la Rosa Rodriguez R, Boyer JL, Assis DN. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. Clinical Pharmacology & Therapeutics 2020, 108: 1213-1223. PMID: 32480421, PMCID: PMC7886378, DOI: 10.1002/cpt.1930.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBile Acids and SaltsBiomarkersCholangitis, SclerosingCytokinesDrug Therapy, CombinationFemaleFenofibrateHumansInflammation MediatorsLiverLiver Cirrhosis, BiliaryLiver Function TestsMaleMiddle AgedPPAR alphaPrincipal Component AnalysisRetrospective StudiesTreatment OutcomeUrsodeoxycholic AcidYoung AdultConceptsPrimary sclerosing cholangitisPrimary biliary cholangitisBile acid metabolismSclerosing cholangitisBiliary cholangitisBile acidsAcid metabolismPeroxisome proliferator-activated receptor alphaProliferator-activated receptor alphaRetrospective observational studyBeneficial clinical effectsCholestatic liver diseasePro-inflammatory cytokinesBile acid metabolitesHealthy control subjectsBile acid poolSerum alkaline phosphataseAminotransferase abnormalitiesUrsodiol therapyFenofibrate therapyPartial respondersBile acid precursorsClinical effectsFenofibrate treatmentLiver disease
2019
2797 Fenofibrate and PSC: A Case Series From a Single Center Liver Registry
Shah S, Silveira M, Assis D, Cusack L. 2797 Fenofibrate and PSC: A Case Series From a Single Center Liver Registry. The American Journal Of Gastroenterology 2019, 114: s1544-s1545. DOI: 10.14309/01.ajg.0000600720.33625.bb.Peer-Reviewed Original ResearchPrimary sclerosing cholangitisPrimary biliary cholangitisCase seriesUrsodeoxycholic acidLarge-duct primary sclerosing cholangitisTreatment of primary sclerosing cholangitisNo current effective therapyRetrospective single-center case seriesPrimary sclerosing cholangitis patientsSingle-center case seriesAlkaline phosphataseRisk scorePrimary sclerosing cholangitis treatmentPost-FFSAlkaline phosphatase reductionPatients due to lackAcute kidney injuryCholestatic liver diseaseAlkaline phosphatase levelsCurrent effective therapiesSerum alkaline phosphataseInflammatory bowel diseaseIntrahepatic diseaseAutoimmune hepatitisRecurrent cholangitis